Puma Biotechnology's Q1 2026 Earnings: NERLYNX Sales, Alisertib Trials, & Growth

Puma Biotechnologys Q1 2026 earnings show a steady performance with $44.8 million revenue, driven by $42 million NERLYNX sales, despite inventory drawdowns and a slight dip in new prescriptions. The sales team is stepping up efforts, with call activity up 44% YoY and 14% QoQ, focusing on high-risk patients and dose escalation. Royalty revenue hit $2.8 million, and NERLYNX is expanding into new markets. Interim data from alisertib trials shows promising single-agent activity in tough cancers like small cell lung and HER2-negative ER-positive breast. Higher doses in lung trials yielded improved PFS, and breast trial combos with endocrine therapy showed strong PFS in specific patient groups. Puma is ramping up doses, expanding breast enrollment, and preparing a lung combo trial. Full-year net income guidance is raised to $16-$19 million, with Q2 product revenue expected at $50-$52 million. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9e5210a219c0559d